Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

AstraZeneca, Anglo American, Tesco: U.K., Irish Equity Preview

June 10 (Bloomberg) -- The following is a list of companies that may have unusual share-price changes in U.K. and Irish markets. Stock symbols are in parentheses and prices are from the last market close.

Futures on the benchmark FTSE 100 Index slid 0.2 percent to 5,844.5 at 7:43 a.m. in London. The FTSE 100 gained 47.45 points, or 0.8 percent, to 5,856.34 yesterday. The FTSE All-Share Index advanced 0.7 percent to 3,057.04. Ireland’s ISEQ Index rose 1.3 percent to 2,933.78.

AstraZeneca Plc (AZN LN): The drugmaker was downgraded to “underweight” from “overweight” at Barclays Plc. The shares climbed 0.4 percent to 3,174.5 pence.

Anglo American Plc (AAL LN): De Beers Chairman Nicky Oppenheimer said demand for diamonds will exceed production for at least the next five years because no one is starting a new mine.

“For the foreseeable future, five years, it seems to be the demand for diamonds is going to exceed the supply,” Oppenheimer said in a speech at the Council on Foreign Relations in Washington. “That is simply because there are no new mines.”

The shares jumped 2.2 percent to 2,988.5 pence.

Tesco Plc (TSCO LN): The U.K.’s biggest retailer was upgraded to “buy” from “neutral” at Jefferies Group Inc., which cited an attractive valuation. The stock gained 0.2 percent to 409.6 pence.

To contact the reporter on this story: Blanche Gatt in London at bgatt@bloomberg.net

To contact the editor responsible for this story: Andrew Rummer at arummer@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.